Renalytix Plc (RNLXY)

Market Cap	35.24M
Revenue (ttm)	2.89M
Net Income (ttm)	-28.16M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,400
Average Volume	30,286
Open	0.1963
Previous Close	0.2200
Day's Range	0.1963 - 0.2000
52-Week Range	0.1200 - 0.6910
Beta	n/a
RSI	44.80
Earnings Date	Jun 16, 2025

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Employees: 102
• Stock Exchange: OTCMKTS
• Ticker Symbol: RNLXY

Financial Performance

In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.